News

With the emergence of several targeted treatments that have shown efficacy in individuals with germline pathogenic variants, specifically in DNA mismatch repair, the need for germline genetic testing has become even more pronounced.

The FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for the frontline treatment of adults with unresectable, malignant, pleural mesothelioma (MPM), according to Bristol Myers Squibb, the manufacturer of the immunotherapy agents.

To address such disparities, it is important for institutions to embrace and promote the fostering of an inclusive culture and environment for health care professionals of all races and genders, and to adequately equip women specifically with the tools they need to achieve success in the field.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from September 2020.

More than half of the studies surveyed did not alleviate all 3 “cluster” symptoms of pain, fatigue, and sleep disturbances.

Makers of breast implants should supplement their labeling to include a boxed warning about health problems that can arise from the devices, along with a patient decision checklist that highlights those concerns, according to final guidance issued today by the Food and Drug Administration.

The paradigm of advanced nonsquamous non–small cell lung cancer (NSCLC) is now one that necessitates discussions regarding the use of combination chemoimmunotherapy, combination immunotherapy, and single-agent immunotherapy, explained Jonathan Dowell, MD.

A new drug application has been submitted to the FDA for TLX591-CDx, a radiopharmaceutical product that targets prostate-specific membrane antigen, for the imaging of prostate cancer through the use of positron emission tomography.

Cancer is independently associated with mortality in patients admitted to the hospital due to coronavirus disease 2019 (COVID-19) infection.

The new rule outlines procedures for the importation of drugs that were manufactured outside of the United States.

The FDA has granted a fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression, who have progressed on or after a fluoropyrimidine- and platinum-containing chemotherapy, and HER2/neu targeted therapy, if appropriate.

The FDA has granted a priority review to a supplemental new drug application (sNDA) for crizotinib (Xalkori) in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma (ALCL), according to an announcement from Pfizer, Inc.

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma (ccRCC).

The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival (PFS) benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors (pNETs), according to results from the randomized phase 3 SANET-p trial that were presented virtually during the 2020 ESMO Congress.

Patient education is key in reducing stress, so 1 nurse made a 3D model to help better inform her patients.

Patients with mantle cell lymphoma (MCL) who have high-risk biology, including blastoid variant, a Ki-67 score of at least 30%, or high p53 expression, had a significantly shorter failure-free and overall survival (OS), according to results of a retrospective trial.

The advent of immunotherapy has revolutionized multiple areas of cancer treatment, said Timothy Cragin Wang, MD, who added that the transformative potential of the modality has been mild at best in the field of colorectal cancer (CRC).

Most notably, Ginsburg wrote an opinion on the court case United States v. Virginia, which held that all-male admissions policy at the Virginia Military Institute – which was state funded – was unconstitutional.

Nurses need to know where patients are getting their cannabis products and should look out for a few red flags.

At a virtual event Sept. 17, CURE® also named Elizabeth Farrat, B.S.N., RN, CCRN-K, the winner of its first-ever Finest Hour Award for selfless achievements in care during the COVID-19 pandemic.

Nurses should discuss fertility preservation with all eligible patients and provide them with up-to-date information to make their decision.

Patients should not brush their teeth immediately after vomiting, but there are other steps they can take to protect their teeth.

The FDA approved the CINtec PLUS Cytology test to help determine if HPV-positive women need further diagnostic procedures to prevent cervical cancer.

It is crucial that oncology nurses have open lines of communications with their patients when it comes to adverse events.

The FDA has granted a breakthrough therapy designation to magrolimab for the treatment of patients with newly diagnosed myelodysplastic syndrome (MDS), according to an announcement from Gilead Sciences, Inc.

The FDA granted a fast track designation to the highly-selective N-terminal domain inhibitor EPI-7386 for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who are resistant to standard-of-care options, according to an announcement from ESSA Pharma Inc.

As the impact of the coronavirus disease 2019 (COVID-19) pandemic lingers into the later part of 2020, consideration is needed regarding the lasting effects on patients with cancer who may have experienced delayed care or diagnosis.

Nurses play a key role in ensuring that patients with gynecologic cancer understand the results and implications of genetic testing.